A Study of IMP4297 in Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2020-12-16
Target enrollment:
Participant gender:
Summary
This is a Phase I, first-in-human, open-label, dose-escalation study of IMP4297 administered
orally once every day to patients with advanced solid tumors for whom standard therapy either
does not exist or has proven to be ineffective or intolerable. Patients with advanced breast
cancer, ovarian cancer or prostate cancer are preferred. There are two stages to this study:
a dose-escalation stage and a dose-expansion stage.